Cathepsin S is not crucial to TSHR processing and presentation in a murine model of Graves' disease

Immunology

Volumn 116, Issue 4, 2005, Pages 532-540

  Kala, Mrinalini ^a   Chen, Chun Rong ^b   McLachlan, Sandra M ^b   Rapoport, Basil ^b   Aliesky, Holly ^b   Chapman, Harold A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigen presentation; Cysteine proteases; Graves' hyperthyroidism

Indexed keywords

ADENOVIRUS VECTOR; CATHEPSIN S; EPITOPE; PEPTIDE; PROTEIN INHIBITOR; RECOMBINANT THYROTROPIN RELEASING HORMONE RECEPTOR; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE COURSE; EPITOPE MAPPING; FEMALE; GENE DELETION; GENETIC CODE; GRAVES DISEASE; HYPERTHYROIDISM; IMMUNIZATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOANTIBODIES; CATHEPSINS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; GRAVES DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNIZATION; MICE; MICE, INBRED BALB C; RECEPTORS, THYROTROPIN; TH1 CELLS; THYROID GLAND;

EID: 28244451389     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02255.x     Document Type: Article

References (38)

1. Vanderpump MPJ, Tunbridge WMG, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995; 43:55.
2. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocrine Rev 2005; 26:800-32.
3. Shimojo N, Kohno Y, Yamaguchi KI et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin repector and a class II molecule. Proc Natl Acad Sci USA 1999 1995; 93:11074-9.
4. Kaithamana S, Fan J, Osuga Y, Liang SG, Prabhakar BS. Induction of experimental autoimmune Graves' disease in BALB/c mice. J Immunol 1999; 163:5157-64.
5. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J Clin Invest 2000; 105:803-11.
6. Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002; 168:2789-94.
7. Chazenbalk GD, Pichurin P, Chen CR, Latrofa F, Johnstone AP, McLachlan SM, Rapoport B. Thyroid-stimulating autoantibodies in Graves' disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest 2002; 110:209-17.
8. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. J Clin Invest 2003; 111:1897-904.
9. Pichurin PN, Chen CR, Nagayama Y, Pichurina O, Rapoport B, McLachlan SM. Evidence that factors other than particular thyrotropin receptor T cell epitope contribute to the development of hyperthyroidism in murine Graves' disease. Clin Exp Immunol 2004; 135:391-7.
10. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003; 170:3522-7.
11. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and alpha-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol 2004; 173:2167-73.
12. Shi GP, Webb AC, Foster KE, Knoll JH, Lemere CA, Munger JS, Chapman HA. Human cathepsin S. chromosomal localization, gene structure, and tissue distribution. J Biol Chem 1994; 269:11530-6.
13. Petanceska S, Devi L. Sequence analysis, tissue distribution, and expression of rat cathepsin S. J Biol Chem 1992; 267:26038-43.
14. Riese RJ, Woif PR, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA. Essential role for cathepsin S in MHC class II-associated invariant chain procession and peptide loading. Immunity 1996; 4:357-66.
15. Riese RJ, Mitchell RN, Villadangos JA et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998; 101:2351-63.
16. Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: roles of cathepsin S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 1997; 186:549-60.
17. Shi GP, Villadangos JA, Dranoff G et al. Cathepsin S required for normal MHC Class II peptide loading and germinal center development. Immunity 1999; 10:197-206.
18. Pluger EB, Boes M, Alfonso C, Schroter CJ, Kalbacher H, Ploegh HL, Driessen C. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 2002; 32:467-76.
19. Hsieh CS, deRoos P, Honey K, Beers C, Rudensky A. Y. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol 2002; 168:2618-25.
20. + T cells in the periphery and secondary proliferate responses elicited upon peptide challenge. J Immunol 1999; 163:232-41.
21. Rovere P, Zimmermann VS, Forquet F, Demandolx D, Trucy J, Castagnoli P, Davoust J. Dendritic cell maturation and antigen presentation in the absence of invariant chain. Proc Natl Acad Sci USA 1998; 95:1067-72.
22. Nakagawa TY, Brissette WH, Lira PD et al. Impaired invariant chain degradation and antigenic presentation and diminished collagen-induced arthritis in Cathepsin S null mice. Immunity 1999; 10:207-17.
23. Bania J, Gatti E, Lelouard H, David A, Cappello F, Weber E, Camosseto V, Pierre P. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc Natl Acad Sci USA 2003; 100:6664-9.
24. Wu ZQ, Shen Y, Khan AQ, Chu CL, Riese R, Chapman HA, Kanagawa O, Snapper CM. The mechanism underlying T cell help for induction of an antigen-specific in vivo humoral immune response to intact Streptococcus pneumonia is dependent on the type of antigen. J Immunol 2002; 168:5551-7.
25. Nakagawa T, Roth W, Wong P et al. Critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998; 280:450-3.
26. Zhang T, Maekawa Y, Yasumoto K et al. Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major. Biochem Biophys Res Commun 2000; 276:693-701.
27. Zhang T, Maekawa Y, Hanba J et al. Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain in ovalbumin-immunized mice. Immunology 2000; 100:13-20.
28. Nakagawa TY, Brissette WH, Lira PD et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999; 10:207-17.
29. Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, Katunuma N, Hayashi Y. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002; 110:361-9.
30. Yang H, Kala M, Scott BJ, Goluszko E, Chapman HA, Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol 2005; 174:1729-37.
31. Chen CR, Pichurin P, Chazenbalk GD, Aliesky H, Nagayama Y, McLachlan SM, Rapoport B. Low-dose immunization with adenovirus expressing the thyroid-stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease. Endocrinology 2004; 145:228-33.
32. Chazenbalk GD, Jaume JC, McLachlan SM, Rapoport B. Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. J Biol Chem 1997; 272:18959-65.
33. Chazenbalk G, McLachlan SM, Pichurin P, Rapoport B. A 'prion-like' shift between two conformational forms of a recombinant thyrotropin receptor A subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies. J Clin Endocrinol Metab 2001; 86:1287-93.
34. Morris JC, Bergert ER, McCormick DJ. Structure-function studies of the human thyrotropin receptor. Inhibition of binding of labeled thyrotropin (TSH) by synthetic human TSH receptor peptides. J Biol Chem 1993; 268:10900-5.
35. Chen CR, Aliesky H, Pichurin PN, Nagayama Y, McLachlan SM, Rapoport B. Susceptibility rather than resistance to hyperthyroidism is dominant in a thyrotropin receptor adenovirus-induced animal model of Graves' disease as revealed by BALB/c-C57BL/6 hybrid mice. Endocrinology 2004; 145:228-3336.
36. Nagayama Y, McLachlan SM, Rapoport B, Niwa M. A major role for non-MHC genes, but not for microorganisms, in a novel model of Graves' hyperthyroidism. Thyroid 2003; 13:233-8.
37. Shi GP, Bryant RA, Riese R et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000; 191:1177-86.
38. Beers C, Honey K, Fink S, Forbush K, Rudensky YA. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med 2003; 197:169-79.